Drug intelligence / Profile preview

Z010

Development stage: Preclinical
Lead developer: Ziphius
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Z010 is a self-amplifying RNA (saRNA) vaccine candidate being developed by Ziphius Therapeutics for the prevention of coronavirus infections, specifically designed as a 'Pan Corona' vaccine to provide broad protection. Unlike conventional mRNA vaccines, the saRNA platform used in Z010 includes a replicase component that allows the RNA to self-amplify once inside the cell. This mechanism leads to sustained and high-level expression of the encoded coronavirus antigens, which can trigger a robust immune response at lower doses than standard mRNA. Z010 is currently in preclinical development and aims to address multiple variants or types of coronaviruses.

Other names: Ziphius Pan Corona saRNA vaccineZ010-Ziphius-self-amplifying RNA (saRNA)-Pan Corona

Beyond the preview

Go deeper on Z010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Z010.

Explore the full profile